- Home
- ACM vs BMRN Comparison
ACM vs BMRN Comparison
Compare ACM & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACM
- BMRN
- Stock Information
- Founded
- ACM 1980
- BMRN 1996
- Country
- ACM United States
- BMRN United States
- Employees
- ACM N/A
- BMRN N/A
- Industry
- ACM Military/Government/Technical
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- ACM Consumer Discretionary
- BMRN Health Care
- Exchange
- ACM Nasdaq
- BMRN Nasdaq
- Market Cap
- ACM 12.6B
- BMRN 12.1B
- IPO Year
- ACM 2007
- BMRN 1999
- Fundamental
- Price
- ACM $104.36
- BMRN $59.82
- Analyst Decision
- ACM Strong Buy
- BMRN Buy
- Analyst Count
- ACM 9
- BMRN 22
- Target Price
- ACM $118.33
- BMRN $93.43
- AVG Volume (30 Days)
- ACM 978.7K
- BMRN 1.6M
- Earning Date
- ACM 05-05-2025
- BMRN 05-01-2025
- Dividend Yield
- ACM 1.00%
- BMRN N/A
- EPS Growth
- ACM N/A
- BMRN 152.82
- EPS
- ACM 4.58
- BMRN 2.71
- Revenue
- ACM $16,047,510,000.00
- BMRN $2,950,227,000.00
- Revenue This Year
- ACM $6.63
- BMRN $12.27
- Revenue Next Year
- ACM $5.34
- BMRN $9.86
- P/E Ratio
- ACM $22.79
- BMRN $22.11
- Revenue Growth
- ACM 4.55
- BMRN 19.36
- 52 Week Low
- ACM $82.23
- BMRN $52.93
- 52 Week High
- ACM $118.56
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- ACM 68.32
- BMRN 40.34
- Support Level
- ACM $101.13
- BMRN $60.92
- Resistance Level
- ACM $105.75
- BMRN $65.40
- Average True Range (ATR)
- ACM 2.38
- BMRN 1.96
- MACD
- ACM 0.88
- BMRN 0.06
- Stochastic Oscillator
- ACM 90.49
- BMRN 21.52
About ACM AECOM
Aecom is one of the largest global providers of design, engineering, construction, and management services. It serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $16.1 billion in sales in fiscal 2024.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.